Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Oct 15, 2023; 15(10): 1796-1806
Published online Oct 15, 2023. doi: 10.4251/wjgo.v15.i10.1796
Published online Oct 15, 2023. doi: 10.4251/wjgo.v15.i10.1796
Table 2 Patient clinical characteristics
| Overall (n = 134) | Advent Health (n = 62)1 | City of Hope (n = 72) | |
| Child-Pugh class, n (%) | |||
| A | 48 (36) | 26 (42) | 22 (31) |
| B | 54 (40) | 25 (40) | 29 (40) |
| C | 12 (9) | 7 (11) | 5 (7) |
| Not reported | 20 (15) | 4 (6) | 16 (22) |
| BCLC stage, n (%) | |||
| 0 | 1 (1) | 1 (2) | - |
| A | 12 (9) | 2 (3) | 10 (14) |
| B | 25 (19) | 22 (35) | 3 (4) |
| C | 94 (70) | 36 (58) | 58 (81) |
| D | 1 (1) | - | 1 (1) |
| Not reported | 1 (1) | 1 (2) | 0 |
| ECOG, n (%) | |||
| 0 | 28 (21) | 10 (16) | 18 (25) |
| 1 | 103 (77) | 49 (79) | 54 (75) |
| Not reported | 3 (2) | 3 (5) | 0 |
| Etiology, n (%) | |||
| Hepatitis B | 15 (11) | 5 (8) | 10 (14) |
| Hepatitis C | 72 (54) | 35 (56) | 37 (51) |
| Alcohol-related liver disease | 21 (16) | 10 (16) | 11 (15) |
| Nonalcoholic fatty liver disease | 11 (8) | 4 (6) | 7 (10) |
| Not reported/none of the above | 15 (11) | 8 (13) | 7 (10) |
- Citation: Li D, Gruber SB, Iyer S, Gupta S, Tejani M. Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States. World J Gastrointest Oncol 2023; 15(10): 1796-1806
- URL: https://www.wjgnet.com/1948-5204/full/v15/i10/1796.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i10.1796